Keros Therapeutics First Quarter 2025 Earnings: Beats Expectations

Keros Therapeutics (NASDAQ:KROS) First Quarter 2025 Results

Key Financial Results

• Revenue: US$211.2m (up by US$211.2m from 1Q 2024).
• Net income: US$148.5m (up from US$43.1m loss in 1Q 2024).
• Profit margin: 70% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue.
• EPS: US$3.66 (up from US$1.21 loss in 1Q 2024).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Keros Therapeutics Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates significantly.

Looking ahead, revenue is expected to decline by 19% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 17%.

Performance of the American Biotechs industry.

The company's shares are down 5.9% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Keros Therapeutics that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.